In cancer, “de novo” means the first occurrence of a disease in the body. It’s a Latin term that translates to “from the beginning” or “anew,” and oncologists use it in several distinct ways: to describe a cancer diagnosed for the first time (especially when it’s already advanced), a genetic mutation that appeared spontaneously rather than being inherited, or a tumor’s built-in resistance to treatment. The meaning shifts depending on context, so understanding each usage helps make sense of a diagnosis or medical report.
De Novo Metastatic Cancer
The most common way you’ll encounter “de novo” in cancer is when describing metastatic disease found at the very first diagnosis. A person with de novo metastatic breast cancer, for example, already has cancer that has spread to distant organs the moment it’s discovered. This is different from recurrent metastatic cancer, where someone is initially diagnosed with localized disease, undergoes treatment, and then later develops spread to other parts of the body.
The distinction matters more than you might expect. In breast cancer, de novo metastatic disease accounts for roughly 3% to 6% of new diagnoses in high-income countries. Research published in the British Journal of Cancer found that young women with de novo metastatic breast cancer actually survived longer after their metastatic diagnosis than women whose cancer returned and spread after earlier treatment. Patients who relapsed within 12 months of their original diagnosis had about 2.6 times the risk of death compared to the de novo group. Even patients who relapsed more than five years after their initial diagnosis had shorter survival from the point their cancer spread than those who were metastatic from the start.
Why would being diagnosed at a more advanced stage lead to better outcomes than having cancer come back? One likely explanation is biology. Cancer that has already survived chemotherapy, radiation, or surgery may be harder to treat because the most vulnerable cells were already killed off, leaving behind resistant ones. De novo metastatic cancer hasn’t been through that selection process yet, so it may respond better to first-line treatments. The pattern of spread also differs: only about 1% of de novo metastatic breast cancer patients had brain metastases at diagnosis, compared to nearly 19% of those who relapsed within a year.
De Novo vs. Secondary Tumors
Some cancers are classified as “de novo” or “primary” to distinguish them from tumors that evolved out of a less aggressive precursor disease. Glioblastoma, the most aggressive type of brain cancer, is a clear example. A de novo (primary) glioblastoma appears suddenly with no prior history of a brain tumor, typically with symptoms developing over three months or less. A secondary glioblastoma, by contrast, develops over 5 to 10 years from a slower-growing brain tumor called a low-grade astrocytoma.
These two types look the same under a microscope but are genetically distinct. De novo glioblastomas commonly have extra copies of a gene called EGFR that drives cell growth, while secondary glioblastomas are characterized by loss of a tumor-suppressing gene called TP53. These genetic differences influence which treatments work best, making the de novo vs. secondary distinction clinically important rather than just academic.
A similar framework applies to acute myeloid leukemia (AML). De novo AML arises on its own, while secondary AML develops after a previous blood disorder or as a consequence of prior chemotherapy or radiation for a different cancer. International guidelines now treat these distinctions as “diagnostic qualifiers,” meaning clinicians note whether AML progressed from an earlier blood condition or followed prior cancer treatment, but the primary classification is based on the cancer’s genetic profile.
De Novo Mutations in Cancer Genetics
“De novo” also describes genetic mutations that arise spontaneously rather than being passed down from a parent. Every person is born with roughly 45 to 60 brand-new mutations in their DNA that neither parent carried. Most are harmless, but occasionally one lands in a gene that controls cell growth or tumor suppression, potentially raising cancer risk.
These mutations typically occur in a parent’s egg or sperm cell before conception, or in the earliest cell divisions after fertilization. Because they weren’t present in either parent’s body, standard genetic testing of the parents’ blood won’t detect them. Once the mutation is passed to the embryo, however, it can be present in every cell of the child’s body. This is why someone can develop a hereditary cancer syndrome like Li-Fraumeni or retinoblastoma even when there’s no family history of the condition. The mutation is genuinely new in that family’s genetic line.
De Novo Drug Resistance
When oncologists say a cancer has “de novo resistance” to a drug, they mean the cancer was resistant from the very beginning, before any treatment was given. This is different from acquired resistance, where a cancer initially responds to therapy but later stops responding as it adapts.
De novo resistance can stem from the cancer’s own genetic makeup, such as a mutation that blocks a drug’s mechanism of action. It can also come from the tumor’s surrounding environment. Neighboring cells and tissue structures can shield cancer cells from treatment, a form of built-in protection that exists before any drug is introduced. Identifying whether resistance is de novo or acquired helps oncologists decide whether to try a different class of treatment altogether or modify the current approach.
Why the Term Comes Up in Your Records
If you’ve seen “de novo” in a pathology report, medical notes, or while researching a diagnosis, the context tells you which meaning applies. Paired with a cancer stage (especially stage IV), it means the cancer was already advanced at the time of first diagnosis. Paired with a mutation or gene name, it means the genetic change is new and not inherited. Paired with a drug name, it refers to resistance that was present before treatment started. In each case, the core idea is the same: something that originated fresh, without a prior version of itself.